- Scope of the palladium-catalyzed aryl borylation utilizing bis-boronic acid
-
The Suzuki-Miyaura reaction has become one of the more useful tools for synthetic organic chemists. Until recently, there did not exist a direct way to make the most important component in the coupling reaction, namely the boronic acid. Current methods to make boronic acids often employ harsh or wasteful reagents to prepare boronic acid derivatives and require additional steps to afford the desired boronic acid. The scope of the previously reported palladium-catalyzed, direct boronic acid synthesis is unveiled, which includes a wide array of synthetically useful aryl electrophiles. It makes use of the newly available second generation Buchwald XPhos preformed palladium catalyst and bis-boronic acid. For ease of isolation and to preserve the often sensitive C-B bond, all boronic acids were readily converted to their more stable trifluoroborate counterparts.
- Molander, Gary A.,Trice, Sarah L. J.,Kennedy, Steven M.,Dreher, Spencer D.,Tudge, Matthew T.
-
supporting information; experimental part
p. 11667 - 11673
(2012/09/05)
-
- Palladium-catalyzed borylation of aryl and heteroaryl halides utilizing tetrakis(dimethylamino)diboron: One step greener
-
The palladium-catalyzed borylation of aryl and heteroaryl halides with a novel borylating agent, tetrakis(dimethylamino)diboron [(Me2N) 2B-B(NMe2)2], is reported. The method is complementary to the previously reported method utilizing bis-boronic acid (BBA) in that certain substrates perform better under one set of optimized reaction conditions than the other. Because tetrakis(dimethylamino)diboron is the synthetic precursor to both BBA and bis(pinacolato)diboron (B 2Pin2), the new method represents a more atom-economical and efficient approach to current borylation methods.
- Molander, Gary A.,Trice, Sarah L. J.,Kennedy, Steven M.
-
supporting information
p. 4814 - 4817,4
(2012/12/12)
-
- ANTI-CANCER AGENTS ANS USES THEREOF
-
The present invention is in the area of novel compounds and salts thereof, their syntheses, and their use as anti-cancer agents. The compounds include compounds of Formula (I): and solvates, hydrates and pharmaceutically-acceptable salts thereof, wherein A1 is N or CR1; A3 is N or CR3; A5 is N or CR5; R1, R3 R6 and L are defined in the specification; n is 0 or 1; and X is an optionally-substituted aryl group having 6- 10 carbons in the ring portion, an optionally-substituted 6- membered heteroaryl group having 1- 3 nitrogen atoms in the ring portion, an optionally-substituted 5- membered heteroaryl group having 0- 4 nitrogen atoms in the ring portion and optionally having 1 sulfur atom or 1 oxygen atom in the ring portion, or an optionally-substituted heteroaryl group in which a 6- membered ring is fused either to a 5- membered ring or to a 6- membered ring, wherein in each case 1, 2, 3 or 4 ring atoms are heteroatoms independently selected from nitrogen, oxygen and sulfur. They are effective against a broad range of cancers, especially leukemia, prostate, non-small cell lung and colon. They are additionally useful in the treatment of proliferative retinopathies such as diabetic neuropathy and macular degeneration.
- -
-
Page/Page column 68
(2010/11/29)
-
- Anti-cancer agents and uses thereof
-
The present invention is in the area of novel compounds and salts thereof, their syntheses, and their use as anti-cancer agents. The compounds include compounds of Formula I: and solvates, hydrates and pharmaceutically-acceptable salts thereof, wherein A1 is N or CR1; A3 is N or CR3; A5 is N or CR5; R1, R3—R6 and L are defined in the specification; n is 0 or 1; and X is an optionally-substituted aryl group having 6-10 carbons in the ring portion, an optionally-substituted 6-membered heteroaryl group having 1-3 nitrogen atoms in the ring portion, an optionally-substituted 5-membered heteroaryl group having 0-4 nitrogen atoms in the ring portion and optionally having 1 sulfur atom or 1 oxygen atom in the ring portion, or an optionally-substituted heteroaryl group in which a 6-membered ring is fused either to a 5-membered ring or to a 6-membered ring, wherein in each case 1, 2, 3 or 4 ring atoms are heteroatoms independently selected from nitrogen, oxygen and sulfur. They are effective against a broad range of cancers, especially leukemia, non-small cell lung and colon.
- -
-
Page/Page column 26
(2008/06/13)
-
- Farnesyl transferase inhibitors, their preparation, the pharmaceutical compositions which contain them and their use in the preparation of medicaments
-
Novel products of formula (I), their preparation, the pharmaceutical compositions which contain them and their use in the preparation of medicaments. In the formula (I), the following substituents are among the preferred: Ar represents a substituted or co
- -
-
-
- Biaryl-pyridoquinazolinone derivatives as anti-cancer agents
-
This invention provides a compound having the formula: STR1 wherein: (A) n=2-4; (B) R1 and R2 are the same or different and selected from the group consisting of H, (C1 -C3)alkyl, --CH2 CH2 OH, --CH2 CH2 NH2, and --CH2 CH2 N(CH3)2 or R1 and R2 are alkyl moieties which may taken together to form a 4- to 7-membered ring; (C) R3 is selected from H, --CH3, --CH2 CH3, --CH2 CH2 NH2 ; (D) X is located at the 2-, or 3-position and is selected from the group consisting of 2-naphthyl, 1-naphthyl, 1-phenanthrenyl, 2-phenanthrenyl, 3-phenanthrenyl, 4-phenanthrenyl, 9-phenanthrenyl, phenyl, and mono- or polysubstituted phenyl wherein the substituents are selected from the group consisting of --OR4, --NR5 R6, (C1 -C3) alkyl, --CF3, F, Cl, Br, I, --NO2, --CN, --SO3 H, --SO2 NR5 R6, --CO2 H, --CO2 R4, and phenyl; R4 is H or (C1 -C4)alkyl; R5 and R6 are the same or different and are selected from H, or (C1 -C4)alkyl, or R5 and R6 are alkyl groups which may be taken together to form a 4-7 membered ring; (E) W is selected from H, --OR4, --NR5 R6, (C1 -C3)alkyl, --CF3, F, Cl, Br, I, --NO2, --CN, --SO2 NR5 R6, --CO2 R4 ; or a pharmacologically acceptable salt thereof which is useful as an antineoplastic agent.
- -
-
-